Clinical Trial Update: A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immune response and safety of GSK's HPV-16/18 L1 VLP AS04 vaccine (Cervarix) in healthy females aged 15-25. Results were posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2009-12-17